Evotec has bought the German manufacturing operations of Japan’s Central Glass for a nominal €1. The deal is subject to customary closing conditions and is expected to close on 1 November. The business will be renamed Evotec Drug Substance (Germany).

Pharmaceutical CDMO AMRI has invested both in terms of scale and compound handling capabilities and new expert personnel to address orphan and rare disease products. No figure has been disclosed of the sum involved.

At its headquarters site in Albany, New York, AMRI has added additional suites for 10-15 kg batch sizes. At Grafton, Wisconsin, it has expanded its hydrogenation, filtering and drying and analytical capabilities, the latter including LC-MS and GC-MS instruments, as well as new experts. The company has also expanded at Glasgow, UK.